Home - AnaptysBio
AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.
Pipeline - AnaptysBio
AnaptysBio, Inc. 10770 Wateridge Circle Suite 210 San Diego, CA 92121-5801 (858) 362-6295 (ph) [email protected]
About - AnaptysBio
AnaptysBio, Inc. 10770 Wateridge Circle Suite 210 San Diego, CA 92121-5801 . Phone: (858) 362-6295 [email protected]
Science - AnaptysBio
Immune cell modulators are a novel therapeutic class with the potential to deliver differentiated outcomes in autoimmune and inflammatory diseases including dermatology, gastroenterology, …
Overview - AnaptysBio
Rosnilimab is a novel PD-1 depleter and agonist that reduces overactive T cell inflammation. It has two distinct mechanisms of action, depletion and agonism, prevalent both in inflamed …
Anaptys Announces Rosnilimab Achieved Positive Results in RA …
SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, …
News - AnaptysBio, Inc.
SAN DIEGO , Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology …
Working Together to Transform Patient Health - AnaptysBio
We never conduct our interview process via messaging apps, freelance sites or social media platforms (i.e., Google Hangouts, WhatsApp, Signal, etc.). We only communicate with …
Anaptys Announces Positive Top-Line Phase 3 Clinical
SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, …
Rheumatoid Arthritis - AnaptysBio
In Q3 2023, we initiated a global Phase 2 trial of rosnilimab for the treatment of moderate-to-severe rheumatoid arthritis. Read about our February 2025 top-line data here. Updated clinical …
- Some results have been removed